Generated by AI
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors. The company’s product pipeline includes therapies built on its proprietary RPx platform, with candidates aimed at multiple cancer settings. Replimune Group, Inc. serves the oncology market by advancing biologic approaches intended to complement or expand existing cancer treatment options. Headquartered in Woburn, Massachusetts, and founded in 2015, the company operates in the United States and the United Kingdom, with an emphasis on research, development, and commercialization of cancer immunotherapy programs.
Website500 Unicorn Park Drive
Woburn, MA, 01801
United States
The latest articles about REPL.
Summary of Nov 3's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Summary of Aug 10's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about REPL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.